Organic Letters
Letter
Chemistry: From Biophysical Aspects to Clinical Applications; World
Scientific Publishing Company: 2012.
Scheme 1. Variation on Thiofluoroalkyl Sources
(2) (a) Erickson, J. A.; McLoughlin, J. I. J. Org. Chem. 1995, 60, 1626.
́ ́
(b) Araoz, R.; Anhalt, E.; Rene, L.; Badet-Denisot, M.-A.; Courvalin, P.;
Badet, B. Biochemistry 2000, 39, 15971. (c) Romanenko, V. D.; Kukhar,
V. P. Chem. Rev. 2006, 106, 3868.
(3) (a) Ni, C.; Hu, M.; Hu, J. Chem. Rev. 2015, 115, 765. (b) Xu, X. H.;
Matsuzaki, K.; Shibata, N. Chem. Rev. 2015, 115, 731.
(4) Boyer, J.; Arnoult, E.; Medebielle, M.; Guillemont, J.; Unge, J.;
Jochmans, D. J. Med. Chem. 2011, 54, 7974.
(5) (a) Reutrakul, V.; Thongpaisanwong, T.; Tuchinda, P.; Kuhakarn,
C.; Pohmakotr, M. J. Org. Chem. 2004, 69, 6913. (b) Petko, K. I.;
Sokolenko, T. M.; Bezdudny, A. V.; Yagupolskii, L. M. J. Fluorine Chem.
2005, 126, 1342. (c) Li, Y.; Hu, J. J. Fluorine Chem. 2008, 129, 382.
(d) Hu, J. J. Fluorine Chem. 2009, 130, 1130. (e) Jiang, H.; Yuan, S.; Cai,
Y.; Wan, W.; Zhu, S.; Hao, J. J. Fluorine Chem. 2012, 133, 167.
(f) Chernykh, Y.; Beier, P. J. Fluorine Chem. 2013, 156, 307.
(g) Betterley, N. M.; Surawatanawong, P.; Prabpai, S.; Kongsaeree, P.;
Kuhakarn, C.; Pohmakotr, M.; Reutrakul, V. Org. Lett. 2013, 15, 5666.
ceeded well to give the corresponding products 9 and 11,
respectively, indicating that the method is applicable to the
synthesis of various arylthiofluoroalkylated products.
In the investigation described above, we have developed
arylthiofluoroalkylation methods for heteroaromatic and alkene
substrates. By using various arylthiofluoroalkyl sources such as
BrCF2SPh, BrCF2CF2SPh, and BrCF2CF2CF2CF2SPh in visible-
light photocatalysis, two functional groups consisting of sulfur
and fluoroalkyl moieties could be simultaneously installed to
unactivated heteroaromatics and alkenes. The reactivity of the
transformation was highly dependent on the electron density of
the carbon-centered radical intermediate of the arylthiofluor-
oalkyl sources. Therefore, different combinations of photo-
catalyst, base, and solvent were employed, depending on the
observed reactivity. The simultaneous introduction of two
functional groups shows the potential use of the method for
late-stage modifications in the development of functional
molecules. In addition, this method can be easily utilized for
fine-tuning of properties in drug development by controlling the
number of fluorine atoms in reagents.
́
(h) Chernykh, Y.; Jurasek, B.; Beier, P. J. Fluorine Chem. 2015, 171, 162.
(i) Zhu, J.; Ni, C.; Gao, B.; Hu, J. J. Fluorine Chem. 2015, 171, 139.
(6) For some recent reviews on visible-light-induced photocatalysis,
see: (a) Zeitler, K. Angew. Chem., Int. Ed. 2009, 48, 9785. (b) Yoon, T. P.;
Ischay, M. A.; Du, J. Nat. Chem. 2010, 2, 527. (c) Narayanam, J. M. R.;
Stephenson, C. R. J. Chem. Soc. Rev. 2011, 40, 102. (d) Shi, L.; Xia, W.
Chem. Soc. Rev. 2012, 41, 7687. (e) Prier, C. K.; Rankic, D. A.;
MacMillan, D. W. C. Chem. Rev. 2013, 113, 5322. (f) Koike, T.; Akita, M.
Top. Catal. 2014, 57, 967.
(7) For some examples of our recent works in visible-light-induced
photocatalysis, see: (a) Iqbal, N.; Jung, J.; Park, S.; Cho, E. J. Angew.
Chem., Int. Ed. 2014, 53, 539. (b) Yu, C.; Iqbal, N.; Park, S.; Cho, E. J.
Chem. Commun. 2014, 50, 12884. (c) Choi, S.; Chatterjee, T.; Choi, W.
J.; You, Y.; Cho, E. J. ACS Catal. 2015, 5, 4796. (d) Choi, W. J.; Choi, S.;
Ohkubo, K.; Fukuzumi, S.; Cho, E. J.; You, Y. Chem. Sci. 2015, 6, 1454.
(e) Park, S.; Joo, J. M.; Cho, E. J. Chem. -Eur. J. 2015, 2015, 4093.
(f) Chatterjee, T.; Choi, M. G.; Kim, J.; Chang, S. K.; Cho, E. J. Chem.
Commun. 2016, 52, 4203.
(8) Examples of visible light-induced synthesis of SCF3 compounds by
C−S bond formation, see: (a) Straathof, N. J. W.; Tegelbeckers, B. J. P.;
Hessel, V.; Wang, X.; Noel, T. Chem. Sci. 2014, 5, 4768. (b) Honeker, R.;
Garza-Sanchez, R. A.; Hopkinson, M. N.; Glorius, F. Chem. - Eur. J.
ASSOCIATED CONTENT
* Supporting Information
■
S
The Supporting Information is available free of charge on the
Experimental details, additional experimental results,
analytic data for arylthiofluoroalkylated compouds and
2016, 22, 4395. (c) Candish, L.; Pitzer, L.; Gumez-Surez, A. N.; Glorius,
̂
F. Chem. - Eur. J. 2016, 22, 4753.
(9) The Wang group generated −CF2SO2Ph compounds as the
isolable intermediates in their difluoromethylations of heteroaromatics;
see: Su, Y.-M.; Wang, X.-S. Org. Lett. 2014, 16, 2958.
(10) Suda, M.; Hino, C. Tetrahedron Lett. 1981, 22, 1997.
(11) The reactions did not proceed without photocatalyst and visible
(12) (a) Yang, X.; Fang, X.; Yang, X.; Zhao, M.; Han, Y.; Shen, Y.; Wu,
F. Tetrahedron 2008, 64, 2259. (b) Kuhakarn, C.; Surapanich, N.;
Kamtonwong, S.; Pohmakotr, M.; Reutrakul, V. Eur. J. Org. Chem. 2011,
2011, 5911.
AUTHOR INFORMATION
Corresponding Author
■
Author Contributions
∥Y.C. and C.Y. contributed equally.
Notes
The authors declare no competing financial interest.
(13) The optimization process was presented as Table S3 in the
ACKNOWLEDGMENTS
(14) The [NR3]•+ species formed by the photocatalytic pathway bears
acidic α-hydrogen atoms, and it can also serve as a hydrogen donor; see:
refs 7a, b, e, and (a) Du, J.; Espelt, L. R.; Guzei, I. A.; Yoon, T. P. Chem.
Sci. 2011, 2, 2115. (b) Kim, H.; Lee, C. Angew. Chem., Int. Ed. 2012, 51,
12303.
■
This work was supported by the National Research Foundation
of Korea [NRF-2014R1A1A1A05003274, NRF-2014-011165,
and NRF-2012M3A7B4049657] and Dr. Naeem Iqbal (National
Institute of Biotechnology and Genetic Engineering, Pakistan)
for technical assistance.
(15) Zen, J.-M.; Liou, S.-L.; Kumar, A. S.; Hsia, M.-S. Angew. Chem., Int.
Ed. 2003, 42, 577.
REFERENCES
■
(1) (a) Muller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 1881.
̈
(b) Hagmann, W. K. J. Med. Chem. 2008, 51, 4359. (c) O’Hagan, D.
Chem. Soc. Rev. 2008, 37, 308. (d) Purser, S.; Moore, P. R.; Swallow, S.;
Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320. (e) Ojima, I. Fluorine in
Medicinal Chemistry and Chemical Biology: Wiley-Blackwell: 2009.
(f) Gouverneur, V.; Muller, K. Fluorine in Pharmaceutical and Medicinal
D
Org. Lett. XXXX, XXX, XXX−XXX